FDA Orange Book
Is there a generic for Fabior?
Fabior contains tazarotene. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Fabior (tazarotene). The Orange Book shows its last listed patent expires February 24, 2030.
Run it in Rivvi
Map Fabior and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Fabior products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| aerosol, foam, topical | 0.1% | Marketed (Rx) | None | 0 | None |
NDA 202428, held by MAYNE PHARMA LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Fabior patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 10568859 | February 24, 2030 | Drug product | U-2760 | 202428 |
| 10688071 | February 24, 2030 | Drug product | U-2760 | 202428 |
| 8808716 | February 24, 2030 | Drug product | None | 202428 |
Fabior NDC codes
Questions
Is there a generic for Fabior?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Fabior (tazarotene). The Orange Book shows its last listed patent expires February 24, 2030.
What is the generic name for Fabior?
The active ingredient in Fabior is tazarotene, per the FDA Orange Book.
When does the Fabior patent expire?
The last patent listed for Fabior in the Orange Book expires February 24, 2030. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.